Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Xenon Pharmaceuticals Inc.XENE · Entity 2602 | Director | June 05, 2026 | June 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Xenon Pharmaceuticals Inc.
Report date June 05, 2026 · Filed June 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 24,896 |
Reported balance
After 2026-06-05 transaction · row 1
1 source rowRow 1 · 2026-06-05 · Sale · Disposed 1,322 · Balance 24,896 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan, adopted by the reporting person on August 17, 2025, solely to satisfy income tax obligations related to the vesting of RSUs granted on June 5, 2025. |
| Common SharesSEC Table I · non-derivative | IndirectSee Note | 4,902 |
Reported balance
Holding disclosure · report date 2026-06-05 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 4,902 F2: By Gary & Karen Barbara Patou TTEE Patou Family Trust FBO Gary Patou Karen Barbara Patou. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan, adopted by the reporting person on August 17, 2025, solely to satisfy income tax obligations related to the vesting of RSUs granted on June 5, 2025.
F2: By Gary & Karen Barbara Patou TTEE Patou Family Trust FBO Gary Patou Karen Barbara Patou.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 05, 2026 Filed Jun 9, 2026 01:19 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | SaleCommon Shares | 1,322 | $53.14 | $70,251.08 |
DisclosureSEC source: 0001193125-26-262672 · ownership.xml · nonDerivative · entry 1 PATOU GARY · CIK 0001283535 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,896 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan, adopted by the reporting person on August 17, 2025, solely to satisfy income tax obligations related to the vesting of RSUs granted on June 5, 2025. Read SEC document |
| June 03, 2026 Filed Jun 4, 2026 01:04 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | GrantRestricted Share Units · Derivative | 1,593 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-256126 · ownership.xml · derivative · entry 5 PATOU GARY · CIK 0001283535 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,593 Underlying: Common Shares · 1,593 shares Expires not disclosed F4 · derivative.exercise_date: Each RSU represents a contingent right to receive one Common Share vesting 100% on the earlier of (i) June 1, 2027 or (ii) the day before the date of the issuer's 2027 annual meeting of shareholders. F4 · derivative.expiration_date: Each RSU represents a contingent right to receive one Common Share vesting 100% on the earlier of (i) June 1, 2027 or (ii) the day before the date of the issuer's 2027 annual meeting of shareholders. Read SEC document |
| June 03, 2026 Filed Jun 4, 2026 01:04 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | GrantShare Option (Right to Buy) · Derivative | 10,507 | $0.00 Strike: $53.46 | $0.00 |
DisclosureSEC source: 0001193125-26-256126 · ownership.xml · derivative · entry 4 PATOU GARY · CIK 0001283535 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,507 Underlying: Common Shares · 10,507 shares Expires 2036-06-02 F3 · derivative.exercise_date: Vesting 100% on the earlier of (i) June 1, 2027 or (ii) the day before the date of the issuer's 2027 annual meeting of shareholders. Read SEC document |
| June 01, 2026 Filed Jun 4, 2026 01:04 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionRestricted Share Units · Derivative | 2,645 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-256126 · ownership.xml · derivative · entry 3 PATOU GARY · CIK 0001283535 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 2,645 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents Common Shares earned and vested under a restricted share unit ("RSU") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders. F1 · derivative.exercise_date: Represents Common Shares earned and vested under a restricted share unit ("RSU") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders. F1 · derivative.expiration_date: Represents Common Shares earned and vested under a restricted share unit ("RSU") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders. Read SEC document |
| June 01, 2026 Filed Jun 4, 2026 01:04 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionCommon Shares | 2,645 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-256126 · ownership.xml · nonDerivative · entry 1 PATOU GARY · CIK 0001283535 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,218 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents Common Shares earned and vested under a restricted share unit ("RSU") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders. F1 · price: Represents Common Shares earned and vested under a restricted share unit ("RSU") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders. Read SEC document |
| June 05, 2025 Filed Jun 6, 2025 22:00 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | GrantRestricted Share Units · Derivative | 2,645 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-083329 · ownership.xml · derivative · entry 2 PATOU GARY · CIK 0001283535 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,645 Underlying: Common Shares · 2,645 shares Expires not disclosed F2 · derivative.exercise_date: Each restricted share unit represents a contingent right to receive one Common Share vesting 100% on the earlier of (i) June 4, 2026 or (ii) the day before the date of the issuer's 2026 annual meeting of shareholders. F2 · derivative.expiration_date: Each restricted share unit represents a contingent right to receive one Common Share vesting 100% on the earlier of (i) June 4, 2026 or (ii) the day before the date of the issuer's 2026 annual meeting of shareholders. Read SEC document |
| June 05, 2025 Filed Jun 6, 2025 22:00 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | GrantShare Option (Right to Buy) · Derivative | 17,012 | $0.00 Strike: $30.73 | $0.00 |
DisclosureSEC source: 0000950170-25-083329 · ownership.xml · derivative · entry 1 PATOU GARY · CIK 0001283535 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,012 Underlying: Common Shares · 17,012 shares Expires 2035-06-04 F1 · derivative.exercise_date: Vesting 100% on the earlier of (i) June 4, 2026 or (ii) the day before the date of the issuer's 2026 annual meeting of shareholders. Read SEC document |
| November 22, 2024 Filed Nov 23, 2024 00:48 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,086 | $0.00 Strike: $13.48 | $0.00 |
DisclosureSEC source: 0000950170-24-130378 · ownership.xml · derivative · entry 9 PATOU GARY · CIK 0001283535 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 3,086 shares Expires 2025-05-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| November 22, 2024 Filed Nov 23, 2024 00:48 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,500 | $0.00 Strike: $7.38 | $0.00 |
DisclosureSEC source: 0000950170-24-130378 · ownership.xml · derivative · entry 8 PATOU GARY · CIK 0001283535 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 3,500 shares Expires 2026-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| November 22, 2024 Filed Nov 23, 2024 00:48 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | SaleCommon Shares | 2,040 | $41.05 | $83,742.00 |
DisclosureSEC source: 0000950170-24-130378 · ownership.xml · nonDerivative · entry 6 PATOU GARY · CIK 0001283535 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,573 Read SEC document |
| November 22, 2024 Filed Nov 23, 2024 00:48 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Tax withholdingCommon Shares | 1,046 | $39.80 | $41,630.80 |
DisclosureSEC source: 0000950170-24-130378 · ownership.xml · nonDerivative · entry 5 PATOU GARY · CIK 0001283535 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,613 F1 · price: Represents the closing price of the Company's common shares on November 21, 2024 for purposes of net settlement calculations. Read SEC document |
| November 22, 2024 Filed Nov 23, 2024 00:48 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionCommon Shares | 3,086 | $13.48 | $41,599.28 |
DisclosureSEC source: 0000950170-24-130378 · ownership.xml · nonDerivative · entry 4 PATOU GARY · CIK 0001283535 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,659 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 22, 2024 Filed Nov 23, 2024 00:48 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | SaleCommon Shares | 2,851 | $41.11 | $117,204.61 |
DisclosureSEC source: 0000950170-24-130378 · ownership.xml · nonDerivative · entry 3 PATOU GARY · CIK 0001283535 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,573 Read SEC document |
| November 22, 2024 Filed Nov 23, 2024 00:48 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Tax withholdingCommon Shares | 649 | $39.80 | $25,830.20 |
DisclosureSEC source: 0000950170-24-130378 · ownership.xml · nonDerivative · entry 2 PATOU GARY · CIK 0001283535 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,424 F1 · price: Represents the closing price of the Company's common shares on November 21, 2024 for purposes of net settlement calculations. Read SEC document |
| November 22, 2024 Filed Nov 23, 2024 00:48 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionCommon Shares | 3,500 | $7.38 | $25,830.00 |
DisclosureSEC source: 0000950170-24-130378 · ownership.xml · nonDerivative · entry 1 PATOU GARY · CIK 0001283535 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,073 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 05, 2024 Filed Jun 5, 2024 21:43 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | GrantStock Option (Right to Buy) · Derivative | 15,542 | $0.00 Strike: $38.16 | $0.00 |
DisclosureSEC source: 0000950170-24-069468 · ownership.xml · derivative · entry 1 PATOU GARY · CIK 0001283535 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,542 Underlying: Common Shares · 15,542 shares Expires 2034-06-04 F1 · derivative.exercise_date: Vesting 100% on the earlier of (i) June 4, 2025 or (ii) the day before the date of the issuer's 2025 annual meeting of shareholders. Read SEC document |
| December 14, 2023 Filed Dec 16, 2023 02:50 UTC Amendment | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | SaleCommon Shares | 7,598 | $41.05 | $311,897.90 |
DisclosureSEC source: 0000950170-23-070912 · ownership.xml · nonDerivative · entry 1 PATOU GARY · CIK 0001283535 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Note Disclosed balance after: 4,902 F1 · shares: Pursuant to the terms of a Lock-Up Agreement executed by the Reporting Person in favor of the underwriters of the Company's follow-on public offering in November 2023, the Reporting Person is permitted to transfer up to 22,000 common shares beneficially owned prior to November 29, 2023 or received upon the exercise of an option to purchase common shares during the lock-up period. F2 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $41.00 to $41.06, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. F3 · ownership.nature: By Gary & Karen Barbara Patou TTEE Patou Family Trust FBO Gary Patou Karen Barbara Patou. Read SEC document |
| December 13, 2023 Filed Dec 15, 2023 22:38 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,144 | $0.00 Strike: $9.00 | $0.00 |
DisclosureSEC source: 0000950170-23-070841 · ownership.xml · derivative · entry 13 PATOU GARY · CIK 0001283535 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 5,144 shares Expires 2024-11-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 13, 2023 Filed Dec 15, 2023 22:38 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,800 | $0.00 Strike: $9.85 | $0.00 |
DisclosureSEC source: 0000950170-23-070841 · ownership.xml · derivative · entry 12 PATOU GARY · CIK 0001283535 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 2,800 shares Expires 2024-01-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The exercise price was converted to U.S. dollars from $10.78 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. Read SEC document |
| December 13, 2023 Filed Dec 15, 2023 22:38 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,378 | $0.00 Strike: $9.85 | $0.00 |
DisclosureSEC source: 0000950170-23-070841 · ownership.xml · derivative · entry 11 PATOU GARY · CIK 0001283535 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 6,378 shares Expires 2024-01-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The exercise price was converted to U.S. dollars from $10.78 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. Read SEC document |
| December 13, 2023 Filed Dec 15, 2023 22:38 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | SaleCommon Shares | 7,598 | $41.05 | $311,897.90 |
DisclosureSEC source: 0000950170-23-070841 · ownership.xml · nonDerivative · entry 10 PATOU GARY · CIK 0001283535 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Note Disclosed balance after: 4,902 F1 · shares: Pursuant to the terms of a Lock-Up Agreement executed by the Reporting Person in favor of the underwriters of the Company's follow-on public offering in November 2023, the Reporting Person is permitted to transfer up to 22,000 common shares beneficially owned prior to November 29, 2023 or received upon the exercise of an option to purchase common shares during the lock-up period. F6 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $41.00 to $41.06, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. F7 · ownership.nature: By Gary & Karen Barbara Patou TTEE Patou Family Trust FBO Gary Patou Karen Barbara Patou. Read SEC document |
| December 13, 2023 Filed Dec 15, 2023 22:38 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | SaleCommon Shares | 3,977 | $39.84 | $158,443.68 |
DisclosureSEC source: 0000950170-23-070841 · ownership.xml · nonDerivative · entry 9 PATOU GARY · CIK 0001283535 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,573 F1 · shares: Pursuant to the terms of a Lock-Up Agreement executed by the Reporting Person in favor of the underwriters of the Company's follow-on public offering in November 2023, the Reporting Person is permitted to transfer up to 22,000 common shares beneficially owned prior to November 29, 2023 or received upon the exercise of an option to purchase common shares during the lock-up period. Read SEC document |
| December 13, 2023 Filed Dec 15, 2023 22:38 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Tax withholdingCommon Shares | 1,167 | $39.68 | $46,306.56 |
DisclosureSEC source: 0000950170-23-070841 · ownership.xml · nonDerivative · entry 8 PATOU GARY · CIK 0001283535 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,550 F1 · shares: Pursuant to the terms of a Lock-Up Agreement executed by the Reporting Person in favor of the underwriters of the Company's follow-on public offering in November 2023, the Reporting Person is permitted to transfer up to 22,000 common shares beneficially owned prior to November 29, 2023 or received upon the exercise of an option to purchase common shares during the lock-up period. F3 · price: Represents the closing price of the Company's common shares in U.S. dollars on December 12, 2023, which was converted to a Canadian dollar amount for purposes of net settlement calculations. Read SEC document |
| December 13, 2023 Filed Dec 15, 2023 22:38 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionCommon Shares | 5,144 | $9.00 | $46,296.00 |
DisclosureSEC source: 0000950170-23-070841 · ownership.xml · nonDerivative · entry 7 PATOU GARY · CIK 0001283535 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,717 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Pursuant to the terms of a Lock-Up Agreement executed by the Reporting Person in favor of the underwriters of the Company's follow-on public offering in November 2023, the Reporting Person is permitted to transfer up to 22,000 common shares beneficially owned prior to November 29, 2023 or received upon the exercise of an option to purchase common shares during the lock-up period. Read SEC document |
| December 13, 2023 Filed Dec 15, 2023 22:38 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | SaleCommon Shares | 2,303 | $39.10 | $90,047.30 |
DisclosureSEC source: 0000950170-23-070841 · ownership.xml · nonDerivative · entry 6 PATOU GARY · CIK 0001283535 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,573 F1 · shares: Pursuant to the terms of a Lock-Up Agreement executed by the Reporting Person in favor of the underwriters of the Company's follow-on public offering in November 2023, the Reporting Person is permitted to transfer up to 22,000 common shares beneficially owned prior to November 29, 2023 or received upon the exercise of an option to purchase common shares during the lock-up period. F5 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $39.04 to $39.16, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| December 13, 2023 Filed Dec 15, 2023 22:38 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Tax withholdingCommon Shares | 577 | $39.68 | $22,895.36 |
DisclosureSEC source: 0000950170-23-070841 · ownership.xml · nonDerivative · entry 5 PATOU GARY · CIK 0001283535 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,876 F1 · shares: Pursuant to the terms of a Lock-Up Agreement executed by the Reporting Person in favor of the underwriters of the Company's follow-on public offering in November 2023, the Reporting Person is permitted to transfer up to 22,000 common shares beneficially owned prior to November 29, 2023 or received upon the exercise of an option to purchase common shares during the lock-up period. F3 · price: Represents the closing price of the Company's common shares in U.S. dollars on December 12, 2023, which was converted to a Canadian dollar amount for purposes of net settlement calculations. Read SEC document |
| December 13, 2023 Filed Dec 15, 2023 22:38 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionCommon Shares | 2,880 | $9.85 | $28,368.00 |
DisclosureSEC source: 0000950170-23-070841 · ownership.xml · nonDerivative · entry 4 PATOU GARY · CIK 0001283535 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,453 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Pursuant to the terms of a Lock-Up Agreement executed by the Reporting Person in favor of the underwriters of the Company's follow-on public offering in November 2023, the Reporting Person is permitted to transfer up to 22,000 common shares beneficially owned prior to November 29, 2023 or received upon the exercise of an option to purchase common shares during the lock-up period. F2 · price: The exercise price was converted to U.S. dollars from $10.78 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. Read SEC document |
| December 13, 2023 Filed Dec 15, 2023 22:38 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | SaleCommon Shares | 5,100 | $38.94 | $198,594.00 |
DisclosureSEC source: 0000950170-23-070841 · ownership.xml · nonDerivative · entry 3 PATOU GARY · CIK 0001283535 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,573 F1 · shares: Pursuant to the terms of a Lock-Up Agreement executed by the Reporting Person in favor of the underwriters of the Company's follow-on public offering in November 2023, the Reporting Person is permitted to transfer up to 22,000 common shares beneficially owned prior to November 29, 2023 or received upon the exercise of an option to purchase common shares during the lock-up period. F4 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $38.81 to $39.13, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| December 13, 2023 Filed Dec 15, 2023 22:38 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Tax withholdingCommon Shares | 1,278 | $39.68 | $50,711.04 |
DisclosureSEC source: 0000950170-23-070841 · ownership.xml · nonDerivative · entry 2 PATOU GARY · CIK 0001283535 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,673 F1 · shares: Pursuant to the terms of a Lock-Up Agreement executed by the Reporting Person in favor of the underwriters of the Company's follow-on public offering in November 2023, the Reporting Person is permitted to transfer up to 22,000 common shares beneficially owned prior to November 29, 2023 or received upon the exercise of an option to purchase common shares during the lock-up period. F3 · price: Represents the closing price of the Company's common shares in U.S. dollars on December 12, 2023, which was converted to a Canadian dollar amount for purposes of net settlement calculations. Read SEC document |
| December 13, 2023 Filed Dec 15, 2023 22:38 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionCommon Shares | 6,378 | $9.85 | $62,823.30 |
DisclosureSEC source: 0000950170-23-070841 · ownership.xml · nonDerivative · entry 1 PATOU GARY · CIK 0001283535 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,951 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Pursuant to the terms of a Lock-Up Agreement executed by the Reporting Person in favor of the underwriters of the Company's follow-on public offering in November 2023, the Reporting Person is permitted to transfer up to 22,000 common shares beneficially owned prior to November 29, 2023 or received upon the exercise of an option to purchase common shares during the lock-up period. F2 · price: The exercise price was converted to U.S. dollars from $10.78 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. Read SEC document |
| June 02, 2023 Filed Jun 2, 2023 21:27 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | GrantStock Option (Right to Buy) · Derivative | 18,475 | $0.00 Strike: $38.96 | $0.00 |
DisclosureSEC source: 0000950170-23-026190 · ownership.xml · derivative · entry 1 PATOU GARY · CIK 0001283535 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,475 Underlying: Common Shares · 18,475 shares Expires 2033-06-01 F1 · derivative.exercise_date: Vesting 100% on the earlier of (i) June 1, 2024 or (ii) the day immediately preceding the day of the following year's annual meeting. Read SEC document |
| November 25, 2022 Filed Nov 29, 2022 01:41 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,057 | $0.00 Strike: $2.68 | $0.00 |
DisclosureSEC source: 0001209191-22-058916 · doc4.xml · derivative · entry 6 PATOU GARY · CIK 0001283535 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 2,057 shares Expires 2022-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The exercise price was converted to U.S. dollars from $2.67 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. F6 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| November 25, 2022 Filed Nov 29, 2022 01:41 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | SaleCommon Shares | 1,937 | $34.79 | $67,390.36 |
DisclosureSEC source: 0001209191-22-058916 · doc4.xml · nonDerivative · entry 4 PATOU GARY · CIK 0001283535 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,573 F4 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $34.76 to $34.90, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| November 25, 2022 Filed Nov 29, 2022 01:41 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Tax withholdingCommon Shares | 120 | $34.37 | $4,124.40 |
DisclosureSEC source: 0001209191-22-058916 · doc4.xml · nonDerivative · entry 3 PATOU GARY · CIK 0001283535 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,510 F3 · price: Represents the closing price of the Company's common shares on November 23, 2022 for purposes of net settlement calculations. Read SEC document |
| November 25, 2022 Filed Nov 29, 2022 01:41 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionCommon Shares | 2,057 | $2.68 | $5,512.76 |
DisclosureSEC source: 0001209191-22-058916 · doc4.xml · nonDerivative · entry 2 PATOU GARY · CIK 0001283535 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,630 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: The exercise price was converted to U.S. dollars from $2.67 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. Read SEC document |
| November 23, 2022 Filed Nov 29, 2022 01:41 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | SaleCommon Shares | 2,057 | $34.33 | $70,609.61 |
DisclosureSEC source: 0001209191-22-058916 · doc4.xml · nonDerivative · entry 1 PATOU GARY · CIK 0001283535 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,573 F1 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $34.24 to $34.36, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| June 28, 2022 Filed Jun 29, 2022 21:40 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | GrantStock Option (Right to Buy) · Derivative | 18,000 | $0.00 Strike: $30.11 | $0.00 |
DisclosureSEC source: 0001209191-22-039833 · doc4.xml · derivative · entry 1 PATOU GARY · CIK 0001283535 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Shares · 18,000 shares Expires 2032-06-27 F1 · derivative.exercise_date: 100% of the common shares subject to the option will vest on the earlier of (i) the first anniversary of grant date and (ii) the day immediately preceding the day of the Issuer's next annual general meeting of shareholders. Read SEC document |
| December 08, 2021 Filed Dec 10, 2021 21:20 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,057 | $0.00 Strike: $3.67 | $0.00 |
DisclosureSEC source: 0001209191-21-069018 · doc4.xml · derivative · entry 3 PATOU GARY · CIK 0001283535 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 2,057 shares Expires 2021-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The exercise price was converted from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. F3 · derivative.exercise_date: 1/3 of the shares subject to the Option vested on January 1, 2013 (the "2012 Vesting Commencement Date") and thereafter the remaining 2/3 of the shares subject to the Option vest each monthly anniversary of the 2012 Vesting Commencement Date over the following 2 years. Read SEC document |
| December 08, 2021 Filed Dec 10, 2021 21:20 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionCommon Shares | 2,057 | $3.67 | $7,549.19 |
DisclosureSEC source: 0001209191-21-069018 · doc4.xml · nonDerivative · entry 1 PATOU GARY · CIK 0001283535 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,630 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The exercise price was converted from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. Read SEC document |
| June 03, 2021 Filed Jun 4, 2021 23:20 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $18.56 | $0.00 |
DisclosureSEC source: 0001209191-21-038431 · doc4.xml · derivative · entry 4 PATOU GARY · CIK 0001283535 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Shares · 10,000 shares Expires 2031-06-02 F3 · derivative.exercise_date: One-third of the total shares subject to the Option shall vest on the one year anniversary of the grant date, one-third of the total shares subject to the Option shall vest on the two year anniversary of the grant date, one-third of the total shares subject to the Option shall vest on the three year anniversary of the grant date. Read SEC document |
| March 17, 2021 Filed Jun 4, 2021 23:20 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | OtherCommon Shares | 100 | $19.49 | $1,949.00 |
DisclosureSEC source: 0001209191-21-038431 · doc4.xml · nonDerivative · entry 1 PATOU GARY · CIK 0001283535 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Note Disclosed balance after: 100 F1 · ownership.nature: Shares acquired by the reporting person's son sharing the reporting person's household on the date of acquisition. Subsequent to the acquisition of the reported shares, the reporting person's son no longer shares a household with the reporting person and the reporting person no longer has a reportable beneficial interest in such shares. Subsequent ownership reports filed by the reporting person will not report these shares. Read SEC document |
| October 28, 2020 Filed Oct 29, 2020 20:20 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,057 | $0.00 Strike: $3.76 | $0.00 |
DisclosureSEC source: 0001209191-20-056222 · doc4.xml · derivative · entry 3 PATOU GARY · CIK 0001283535 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 2,057 shares Expires 2020-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The exercise price was converted from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. F3 · derivative.exercise_date: The shares subject to the option fully vested on December 31, 2013. The date the options became fully vested was incorrectly reflected on the Reporting Person's Form 3. Read SEC document |
| October 28, 2020 Filed Oct 29, 2020 20:20 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionCommon Shares | 2,057 | $3.76 | $7,734.32 |
DisclosureSEC source: 0001209191-20-056222 · doc4.xml · nonDerivative · entry 1 PATOU GARY · CIK 0001283535 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,573 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The exercise price was converted from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. Read SEC document |
| June 01, 2020 Filed Jun 2, 2020 21:32 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $13.11 | $0.00 |
DisclosureSEC source: 0001209191-20-033653 · doc4.xml · derivative · entry 1 PATOU GARY · CIK 0001283535 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Shares · 10,000 shares Expires 2030-05-31 F1 · derivative.exercise_date: One-third of the total shares subject to the Option shall vest on the one year anniversary of the grant date, one-third of the total shares subject to the Option shall vest on the two year anniversary of the grant date, one-third of the total shares subject to the Option shall vest on the three year anniversary of the grant date. Read SEC document |
| December 04, 2019 Filed Dec 6, 2019 22:12 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,057 | $0.00 Strike: $3.56 | $0.00 |
DisclosureSEC source: 0001209191-19-059515 · doc4.xml · derivative · entry 3 PATOU GARY · CIK 0001283535 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 2,057 shares Expires 2019-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The exercise price was converted from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. F3 · derivative.exercise_date: The shares subject to the option fully vested on December 31, 2012. The date the options became fully vested was incorrectly reflected on the Reporting Person's Form 3. Read SEC document |
| December 04, 2019 Filed Dec 6, 2019 22:12 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionCommon Shares | 2,057 | $3.56 | $7,322.92 |
DisclosureSEC source: 0001209191-19-059515 · doc4.xml · nonDerivative · entry 1 PATOU GARY · CIK 0001283535 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,516 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The exercise price was converted from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. Read SEC document |
| September 16, 2019 Filed Sep 18, 2019 22:51 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $9.44 | $0.00 |
DisclosureSEC source: 0001209191-19-050146 · doc4.xml · derivative · entry 1 PATOU GARY · CIK 0001283535 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Shares · 15,000 shares Expires 2029-09-15 F1 · derivative.exercise_date: One-third of the total shares subject to the Option shall vest on the one year anniversary of the grant date, one-third of the total shares subject to the Option shall vest on the two year anniversary of the grant date, one-third of the total shares subject to the Option shall vest on the three year anniversary of the grant date. Read SEC document |
| December 14, 2018 Filed Dec 18, 2018 21:06 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,057 | $0.00 Strike: $3.07 | $0.00 |
DisclosureSEC source: 0001171843-18-008471 · ownership.xml · derivative · entry 3 PATOU GARY · CIK 0001283535 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 2,057 shares Expires 2018-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: By Gary & Karen Barbara Patou TTEE Patou Family Trust FBO Gary Patou Karen Barbara Patou. F3 · derivative.exercise_date: The shares subject to the option fully vested on December 31, 2011. Read SEC document |
| December 14, 2018 Filed Dec 18, 2018 21:06 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionCommon Shares | 2,057 | $3.07 | $6,314.99 |
DisclosureSEC source: 0001171843-18-008471 · ownership.xml · nonDerivative · entry 1 PATOU GARY · CIK 0001283535 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,459 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The exercise price was converted to U.S. dollars from $3.74 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the day of exercise. Read SEC document |
| June 14, 2018 Filed Jun 15, 2018 23:32 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,230 | $0.00 Strike: $3.70 | $0.00 |
DisclosureSEC source: 0001171843-18-004695 · formfour.xml · derivative · entry 4 PATOU GARY · CIK 0001283535 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 8,230 shares Expires 2018-06-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The exercise price was converted to U.S. dollars from $3.74 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the day of exercise. F4 · derivative.exercise_date: The shares subject to the option fully vested on May 31, 2011. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.